Molecular hydrogen is associated with immunophenotypic modulation and changes in T-cell exhaustion markers in refractory primary Sjögren’s syndrome-associated interstitial lung disease: A case report.
Wei-Hung Hsu, Jeng-Wei Lu, Yi-Jung Ho, Shan-Wen Lui, Ting-Yu Hsieh, Kuang-Yih Wang, Feng-Cheng Liu · SAGE open medical case reports · 2026
Research-use notice
Independent study record
Each H2HUBB study page organizes source-linked research details for educational use. Interpretation should remain proportional to the study design, population, controls, and limitations.
H2HUBB TAKEAWAY
In a patient with progressive Sjögren's syndrome-associated interstitial lung disease, these findings suggest hydrogen therapy as a safe and potentially beneficial adjunctive strategy for refractory autoimmune fibrotic diseases, supporting further clinical validation. These findings add human evidence supporting molecular hydrogen's therapeutic potential across the specific human outcomes evaluated in this study.
What the Findings Mean
H2HUBB reviewed how molecular hydrogen affected the outcomes measured in a patient with progressive Sjögren's syndrome-associated interstitial lung disease. These findings suggest hydrogen therapy as a safe and potentially beneficial adjunctive strategy for refractory autoimmune fibrotic diseases, supporting further clinical validation.
What the Researchers Studied
The researchers studied a patient with progressive Sjögren's syndrome-associated interstitial lung disease.
What Effects Did Molecular Hydrogen Have?
This report evaluates the therapeutic potential of hydrogen in a patient with progressive Sjögren's syndrome-associated interstitial lung disease. These findings suggest hydrogen therapy as a safe and potentially beneficial adjunctive strategy for refractory autoimmune fibrotic diseases, supporting further clinical validation. Molecular hydrogen has recently emerged as a novel therapeutic agent known for its selective antioxidant, anti-inflammatory, and immunomodulatory properties. sj-pdf-1-sco-10.1177_2050313X261454858 – Supplemental material for Molecular hydrogen is associated with immunophenotypic modulation and changes in T-cell exhaustion markers in refractory primary Sjögren’s syndrome-associated interstitial lung disease. A case report Supplemental material, sj-pdf-1-sco-10.1177_2050313X261454858 for Molecular hydrogen is associated with immunophenotypic modulation and changes in T-cell exhaustion markers in refractory primary Sjögren’s syndrome-associated interstitial lung disease: A case report by Wei-Hung Hsu, Jeng-Wei Lu, Yi-Jung Ho, Shan-Wen Lui, Ting-Yu Hsieh, Kuang-Yih Wang and Feng-Cheng Liu in SAGE Open Medical Case Reports. While these findings suggest that H₂ may exert multifaceted therapeutic effects by modulating oxidative stress, inflammation, and immune dysregulation, 31 the discussion of causality warrants a cautious interpretation.
Why These Findings Matter
These findings add human evidence supporting molecular hydrogen's therapeutic potential across the specific human outcomes evaluated in this study and contribute to the growing body of molecular-hydrogen research.
How Strong Is This Evidence?
This is human clinical evidence from a case report. H2HUBB interprets the findings in the context of the study design, sample, comparator, and measured outcomes rather than using one publication as a verdict on hydrogen therapy.
Technical Study Details
H2HUBB classifies this publication as case report with human clinical evidence. The research population or model was a patient with progressive Sjögren's syndrome-associated interstitial lung disease.
Limitations and Safety
Reported limitations: Given the inherent limitations of a single case report, these observations remain hypothesis-generating and are not generalizable.
Original Study and H2HUBB Research Context
H2HUBB presents this source-grounded research record as one contribution to the broader molecular-hydrogen evidence base.